TY - JOUR
T1 - Investigations on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant human interleukin-2
AU - Vourka-Karussis, U.
AU - Levi-Schaffer, F.
AU - Slavin, S.
PY - 1993
Y1 - 1993
N2 - Human recombinant interleukin-2 (rIL-2) was used in an effort to find effective biological therapy against the murine B-cell leukemia (BCL1), a spontaneous, nonimmunogenic, highly lethal leukemia of Balb/c origin. High dose rIL-2 (105 Cetus units 3 times a day for 5 days) was proven to be curative for mice inoculated with up to 104 BCL1 cells. Considering the fact that mice which showed more clinical signs of rIL-2 related toxicity had higher leukemia-free survival, and in view of the fact that BCL1 is a totally nonimmunogenic tumor, we have investigated the possible role of nonspecific effects of inflammatory and anti-inflammatory agents in order to speculate on the possible therapeutic role of inflammation on the overall effect of rIL-2 in the treatment of BCL1. According to the results presented in this work, it appears that although mediators of inflammation may play some role against leukemia, their overall effect in comparison with high-dose rIL-2 is relatively insignificant.
AB - Human recombinant interleukin-2 (rIL-2) was used in an effort to find effective biological therapy against the murine B-cell leukemia (BCL1), a spontaneous, nonimmunogenic, highly lethal leukemia of Balb/c origin. High dose rIL-2 (105 Cetus units 3 times a day for 5 days) was proven to be curative for mice inoculated with up to 104 BCL1 cells. Considering the fact that mice which showed more clinical signs of rIL-2 related toxicity had higher leukemia-free survival, and in view of the fact that BCL1 is a totally nonimmunogenic tumor, we have investigated the possible role of nonspecific effects of inflammatory and anti-inflammatory agents in order to speculate on the possible therapeutic role of inflammation on the overall effect of rIL-2 in the treatment of BCL1. According to the results presented in this work, it appears that although mediators of inflammation may play some role against leukemia, their overall effect in comparison with high-dose rIL-2 is relatively insignificant.
KW - IL-2
KW - Inflammation
KW - Leukemia
UR - http://www.scopus.com/inward/record.url?scp=0027819340&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 7678091
AN - SCOPUS:0027819340
SN - 0301-472X
VL - 21
SP - 93
EP - 97
JO - Experimental Hematology
JF - Experimental Hematology
IS - 1
ER -
